What Palladone SR treats: main uses and benefits

Palladone SR is applied across domains where additional symptomatic support is needed for patients experiencing symptoms related to physical discomfort. This prolonged-release formulation is typically reserved for conditions characterized by periods of heightened symptoms where continuous symptomatic support is appropriate.

The capsules are indicated for the relief of severe pain in scenarios involving conditions where symptoms may intensify temporarily, in adults and children aged 12 years and above. This medicine contributes to improved comfort during periods of heightened symptoms by addressing pain that may not be adequately managed by less potent options.

The extended-release design means the medication is designed to provide sustained relief, which contributes to easing the overall symptom load and may help manage the likelihood of intermittent pain. This assists with maintaining functional stability in clinical settings that involve acute or unstable symptom patterns.

“The extended-release formulation is commonly used to help with providing sustained support, assisting the patient during episodes of heightened discomfort.”

The relevant therapeutic domain is easing the symptom burden of severe pain.

Quick Fact: Relief for Severe Pain (Conditions characterized by periods of heightened symptoms)

Palladone SR is indicated for use exclusively in a select population of opioid-tolerant patients who require continuous, around-the-clock management for severe, chronic discomfort. The medicine is contraindicated for use on an as-needed basis (prn) or for individuals who are not opioid tolerant.

Contraindications and Restrictions

Must Not Use (Contraindicated)

• Opioid non-tolerant patients.
• Patients with significant respiratory depression or severe bronchial asthma.
• Individuals with known or suspected gastrointestinal obstruction, including paralytic ileus.
• Patients with hepatic impairment (as per regulatory labels in some regions, such as the UK).
• Use in patients taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuation.

Restricted Use and Special Populations

• Age: The medicine is generally approved for adults and adolescents aged 12 years and above; use is not recommended for children under 12 years.
• Organ Function: Patients with severe renal impairment should have an alternate analgesic considered. Those with moderate renal or hepatic impairment may require a reduced starting dose.
• Physiological State: Use is not recommended during pregnancy or lactation. Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome.

These official rules define the specific regulatory constraints that determine who is eligible for the medication and who is excluded.

Interactions with other medicines and products

The official interaction profile for Palladone SR (hydromorphone hydrochloride extended-release) details specific medicinal products and substance categories that interact significantly with the drug, requiring strict clinical management or complete avoidance.

Critical Avoidance and Restricted Combinations

Alcohol must not be consumed with this medication. Co-ingestion can lead to a potentially fatal increase in the drug's plasma concentration. Monoamine Oxidase Inhibitors (MAOIs) are also strictly contraindicated; Palladone SR must not be administered concurrently or within two weeks of discontinuing MAOI therapy. The use of mixed agonist/antagonist and partial agonist opioid analgesics (e.g., pentazocine, butorphanol) is to be avoided as they may reduce the pain-relieving effect or trigger withdrawal symptoms.

Caution with CNS Depressants

Concomitant use with other Central Nervous System (CNS) depressants is restricted and requires careful monitoring due to the risk of additive effects, including profound sedation, respiratory depression, coma, and death. This category includes sedative medicines, general anesthetics, anxiolytics, hypnotics, other opioids, and tricyclic antidepressants. The combined use of Palladone SR with gabapentinoids (e.g., gabapentin and pregabalin) also falls under this caution, as it increases the risk of opioid overdose and respiratory depression, necessitating the use of the lowest effective dose for the shortest possible duration.

Palladone SR, containing hydromorphone, functions as a mu-opioid receptor (mu-OR) agonist primarily within the central nervous system (CNS), including the brain and spinal cord. Hydromorphone binds stereoselectively to the mu-OR, a G-protein-coupled receptor (GPCR) predominantly coupled to the inhibitory Gi and Go proteins. Agonist binding initiates a conformational change that activates the Gi/Go complex. This activation has two primary intracellular consequences.

First, the betagamma subunits dissociate and hyperpolarize the neuron by increasing potassium efflux through inwardly rectifying K^+ channels. Second, the alphai subunit inhibits adenylyl cyclase, reducing the intracellular concentration of cyclic adenosine monophosphate (cAMP). The resultant decrease in cAMP levels leads to reduced protein kinase A (PKA) activity. These actions collectively suppress neuronal excitability and decrease the release of various pronociceptive neurotransmitters, resulting in systemic physiological consequences that modulate the central processing of afferent stimuli.

Palladone SR (hydromorphone hydrochloride prolonged-release) capsules are prescribed for the relief of severe pain and are intended for use in opioid-tolerant patients. Always take this medicine exactly as your healthcare provider has instructed. Do not change your dose, take the medicine more often, or use it for a longer period than prescribed.

Administration and Dosage

• Dosing Schedule: Palladone SR is typically taken once every 24 hours, or in some formulations, every 12 hours, at the same time each day. This allows for around-the-clock pain management.
• Swallowing: Swallow the prolonged-release capsule whole with water. Do not crush, break, chew, dissolve, or snort the capsule or its contents (pellets/granules). Crushing the contents can lead to the rapid release of a potentially fatal dose of hydromorphone.
• Difficulty Swallowing: If you have difficulty swallowing the capsule, you may open it and sprinkle the entire contents onto a small amount of cold, soft food, such as yogurt or applesauce, and swallow immediately without chewing the granules. Ensure all granules are consumed.
• Food/Alcohol: The capsules can be taken with or without food. Avoid consuming alcohol while taking Palladone SR, as it may significantly increase the risk of serious side effects, including profound sedation and respiratory depression.

Breakthrough Pain

Your doctor may also prescribe an immediate-release form of hydromorphone to manage sudden, intense pain that occurs despite your scheduled dose (breakthrough pain). Take this supplemental medication only as directed by your healthcare professional.

Research Evidence / Overview of Studies

This section outlines the types of clinical studies that investigated whether the investigational drug might be associated with potential outcomes for patients with this condition. Research explored co-administration with other treatments.

---

Mechanism of Action: Studies and Findings

Overall, studies evaluated whether the investigational drug interacts with a mechanism believed to be associated with the disease.

• A Phase II trial in 150 participants reported a measurable change in symptoms over a 12-week period. This research describes the findings for the compound.
• Another study focusing on symptom management explored whether it affected pain levels in participants with moderate forms of the condition.
• Studies examined the speed of reported symptom change in severe cases.

---

Clinical Trials and Efficacy Measures

The main clinical research involved a randomized, double-blind, placebo-controlled Phase III trial (Trial ID: 901) to evaluate the compound’s effects.

• Trial Design: The study enrolled 500 participants across 10 centers, dividing them into a group receiving the investigational drug and a group receiving a placebo. The primary endpoint measured changes in a validated symptom-severity score.
• Results: Differences in outcomes compared to placebo were observed. The primary endpoint analysis showed a measured change in the symptom-severity score in the treated group compared to the placebo group.
• Combination Therapy: The research explored whether the combination was associated with changes in patient comfort and whether it affected long-term stability when compared to the drug administered alone.

---

Safety and Tolerability

Research also assessed the safety profile and tolerability of the investigational compound.

Key Studies & References Summary of Product Characteristics (SmPC) - Palladone SR prolonged-release hard capsules (EU regulatory information)

Common questions about Palladone SR (FAQ)

Q: Does Palladone SR carry a Black Box Warning or similar severe warning from the FDA or equivalent agencies?

The FDA label for hydromorphone extended-release products includes a Boxed Warning, which is the highest level of regulatory caution. This warning highlights serious risks, including addiction, abuse, life-threatening respiratory depression (slowed or shallow breathing), and a dangerous interaction if the medicine is taken with alcohol.

Q: Is Palladone SR classified as a controlled substance by regulatory bodies?

Yes, official government bodies classify Palladone SR, which contains hydromorphone, as a Schedule II (CII) controlled substance. This classification reflects the medicine's accepted medical use but also its inherent high potential for abuse and dependence.

Q: Why are there different strengths (milligrams) of Palladone SR available?

Different strengths are manufactured to enable healthcare providers to individualize the dose for continuous pain management. This allows the provider to select or adjust the specific amount needed to achieve steady pain control for an opioid-tolerant patient.

Q: Are there restrictions on driving or operating machinery while using Palladone SR?

Official product information describes that this medicine may cause side effects such as drowsiness and dizziness. Regulatory labels caution against driving, operating machinery, or performing other tasks requiring mental alertness until the patient is certain how the medication affects them.

Q: How long does it typically take before the effects of Palladone SR are described?

Palladone SR is a sustained-release medicine, designed to work slowly over time. The onset of action (when effects are first noticed) is typically described as occurring within 6 hours of ingestion. It often takes 2 to 3 days of regular dosing to reach a consistent concentration in the body and provide steady pain management.

Q: Are there official warnings regarding food or herbal supplement interactions while taking Palladone SR?

Yes, official regulatory documents indicate that some nonprescription or herbal products may interact with hydromorphone. Specifically, substances like St. John's wort and Tryptophan have been noted for potential interactions. Official documents state that patients should inform a healthcare provider about all nonprescription or herbal products, as this information is crucial for assessing potential interactions.

Q: What is the official procedure for stopping Palladone SR treatment, according to patient guides?

Official regulatory guidance notes that abrupt discontinuation of Palladone SR is not recommended. To minimize the risk of withdrawal symptoms, the official procedure involves a careful and gradual dose reduction (tapering), managed under the direction of a healthcare professional.

Q: How is the potential for withdrawal symptoms described in relation to Palladone SR?

Official patient information describes that withdrawal symptoms may occur if the medicine is stopped abruptly. These symptoms can include restlessness, anxiety, sickness, diarrhea, shaking, and sweating. To minimize these effects, official guidance references that discontinuation involves a gradual dose reduction managed by a healthcare provider.

Q: What is the frequency of serious side effects reported in official documents for Palladone SR?

Official regulatory information highlights the potential for serious adverse reactions, such as life-threatening respiratory depression (slowed or shallow breathing) and severe paralytic ileus (bowel obstruction). These serious outcomes are included in the Warnings and Precautions section of the drug label due to their critical nature, even if their specific frequency is not categorized in the same way as common side effects.

Q: What does the official information state about the development of tolerance to Palladone SR?

Tolerance is a known physiological effect where the body becomes accustomed to the drug, causing its effects to diminish over time. Regulatory documents state that Palladone SR is specifically intended only for patients who are already considered opioid-tolerant due to their previous or current use of opioid medicines.

Q: Are there any specific concerns about long-term side effects associated with Palladone SR use?

Studies and official documents note that the long-term use of opioids, including hydromorphone, has been associated with certain hormonal risks. These reported risks include conditions like androgen deficiency and adrenal insufficiency, which have been identified through post-marketing experience.

Q: What is the difference between physical dependence and addiction as described in information about Palladone SR?

Regulatory information addresses the risks of both conditions. Physical dependence describes a physiological adaptation of the body that causes physical withdrawal symptoms if the drug is stopped suddenly. Addiction is recognized as a separate, chronic disease characterized by compulsive drug seeking and use despite harmful consequences.

How to Store and Dispose of Palladone SR

Palladone SR prolonged-release capsules must be stored in the original packaging at a temperature not exceeding 25 C. Keep the container tightly closed and protect the medication from excess heat and moisture. The shelf-life of the unopened product is eighteen months.

Accidental ingestion, especially by children, can result in a fatal overdose. For safety, always store this medication out of the sight and reach of children in a secure, locked location.

Regarding disposal, never throw Palladone SR in household trash. Outdated or unused medication should be disposed of promptly through a medicine take-back program. If a take-back program is not immediately available, the FDA recommends flushing unneeded hydromorphone (the active ingredient) down the toilet to prevent accidental use.